News
LENZ
4.600
-8.73%
-0.440
Lenz drops as BofA downgrades on a slower VIZZ launch
Seeking Alpha · 5h ago
LENZ Therapeutics (LENZ) Stock Reflects Loss Fatigue Despite Long Cash Runway
Simply Wall St · 18h ago
LENZ Therapeutics Price Target Cut to $7.00/Share From $12.00 by Piper Sandler
Dow Jones · 1d ago
LENZ Therapeutics Is Maintained at Neutral by Piper Sandler
Dow Jones · 1d ago
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7
Benzinga · 1d ago
Analyst Maintains Buy on LENZ as VIZZ Adoption, Prescriber Engagement and Patient Refill Trends Support Long-Term Commercial Franchise Growth
TipRanks · 1d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 1d ago
Piper Sandler Sticks to Its Hold Rating for LENZ Therapeutics (LENZ)
TipRanks · 1d ago
Analyst Maintains Buy on LENZ, Cuts VIZZ Price Target to $10 While Highlighting Strong Patient Persistence and Long-Term Upside
TipRanks · 1d ago
Caufield Reiterates Buy on VIZZ as Strong Early Adoption and Expanding Access Channels Support Unchanged $38 Price Target
TipRanks · 1d ago
Analysts Conflicted on These Healthcare Names: C4 Therapeutics (CCCC), Codexis (CDXS) and LENZ Therapeutics (LENZ)
TipRanks · 1d ago
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 2d ago
Press Release: LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Dow Jones · 2d ago
Here are the major earnings after the close Tuesday
Seeking Alpha · 2d ago
LENZ Therapeutics Q2 2026 Earnings Preview
Seeking Alpha · 3d ago
Weekly Report: what happened at LENZ last week (0803-0807)?
Weekly Report · 3d ago
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in July 2026
Seeking Alpha · 08/03 13:45
Weekly Report: what happened at LENZ last week (0727-0731)?
Weekly Report · 08/03 10:13
Weekly Report: what happened at LENZ last week (0720-0724)?
Weekly Report · 07/27 10:17
More
Webull provides a variety of real-time LENZ stock news. You can receive the latest news about LENZ THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About LENZ
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.